Sambong 250mg Tablet for Anti-Urolithiasis (Kidney Stones)

SOH approves the HTAC recommendation on the minor inclusion of sambong 250mg tablet in PNF The Secretary of Health approved the HTAC recommendation on the minor inclusion of sambong 250mg tablet for anti-urolithiasis (kidney stones) in the Philippine National Formulary (PNF) on 14 January 2022. Minor inclusions are applicable to drugs that are currently listed in the continue reading : Sambong 250mg Tablet for Anti-Urolithiasis (Kidney Stones)